Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.
Study Design
- 研究类型
- Randomized Controlled Trial
- 研究人群
- IBS, FC, and IBD patients
- 干预措施
- Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. None
- 对照组
- Control
- 主要结局
- FBD/IBD symptom management
- 效应方向
- Positive
- 偏倚风险
- Unclear
Abstract
UNLABELLED: Functional bowel disorders (FBD), mainly irritable bowel syndrome (IBS) and functional constipation (FC, also called chronic idiopathic constipation), are very common worldwide. Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, although less common, has a strong impact on patients' quality of life, as well as being highly expensive for our healthcare. A definite cure for those disorders is still yet to come. Over the years, several therapeutic approaches complementary or alternative to traditional pharmacological treatments, including probiotics, prebiotics, synbiotics, fibre and herbal medicinal products, have been investigated for the management of both groups of diseases. However, most available studies are biased by several drawbacks, including small samples and poor methodological quality. Probiotics, in particular Saccharomyces boulardii and Lactobacilli (among which Lactobacillus rhamnosus), synbiotics, psyllium, and some herbal medicinal products, primarily peppermint oil, seem to be effective in ameliorating IBS symptoms. Synbiotics and fibre seem to be beneficial in FC patients. The probiotic combination VSL#3 may be effective in inducing remission in patients with mild-to-moderate ulcerative colitis, in whom Escherichia coli Nissle 1917 seems to be as effective as mesalamine in maintaining remission. No definite conclusions can be drawn as to the efficacy of fibre and herbal medicinal products in IBD patients due to the low number of studies and the lack of randomized controlled trials that replicate the results obtained in the individual studies conducted so far. Thus, further, well-designed studies are needed to address the real role of these therapeutic options in the management of both FBD and IBD. LINKED ARTICLES: This article is part of a themed section on Principles of Pharmacological Research of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.11/issuetoc.
简要概述
The probiotic combination VSL#3 may be effective in inducing remission in patients with mild‐to‐moderate ulcerative colitis, in whom Escherichia coli Nissle 1917 seems to be as effective as mesalamine in maintaining remission.
Used In Evidence Reviews
Similar Papers
The American journal of gastroenterology · 2006
Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease.
Phytotherapy research : PTR · 2006
A review of the bioactivity and potential health benefits of peppermint tea (Mentha piperita L.).
The American journal of clinical nutrition · 2001
Protection from gastrointestinal diseases with the use of probiotics.
BMJ (Clinical research ed.) · 2008
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.
Advances in biochemical engineering/biotechnology · 2008
Probiotics, prebiotics, and synbiotics.
World journal of gastroenterology · 2010